Across TCGA pan-cancer cohorts, CSNK2B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CSNK2B data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CSNK2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSNK2B expression acts as an unfavorable survival marker.

DLBC and PRAD are the cancer types where CSNK2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CSNK2B tumor-vs-normal RNA expression · all CSNK2B data types